Erlonib

Erlonib

erlotinib

Manufacturer:

Amarox
Concise Prescribing Info
Contents
Erlotinib
Indications/Uses
1st-line treatment of patients w/ locally advanced or metastatic non-small cell lung cancer stage IIIb/IV w/ EGFR activating mutations; after failure at least 1 prior chemotherapy regimen. In combination w/ gemcitabine in patients w/ locally advanced unresectable or metastatic pancreatic cancer.
Dosage/Direction for Use
Non-small cell lung cancer 150 mg daily. Pancreatic cancer 100 mg daily in combination w/ gemcitabine.
Administration
Should be taken on an empty stomach: Take at least 1 hr before or 2 hr after meals.
Special Precautions
Consider factors associated w/ increased survival.
ATC Classification
L01EB02 - erlotinib ; Belongs to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Erlonib tab 100 mg
Packing/Price
3 × 10's;6 × 10's
Form
Erlonib tab 150 mg
Packing/Price
3 × 10's;6 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in